Cambridge Nutraceuticals (CN), the company which develops and markets health supplements under its brand FutureYou, successfully overfunded in January 2018. The company previously raised just over £1m on SyndicateRoom in 2016.

Cambridge Nutraceuticals raised £1,875,348 via SyndicateRoom in January 2018.

The story

CN is a business which has successfully grown through sales of its launch product Ateronon and is now extending its range of clinically-proven food supplements under a new brand, FutureYou.

CN has a programme of observational and clinical studies at leading research centres, including the Cambridge University Hospitals NHS Foundation Trust and the University of Sheffield.

The company generates revenue principally through sales made directly to UK customers, though the company also has several overseas distributors, with Australia being a particularly significant market. The product is monetised as the company has calculated the ‘lifetime value’ of a customer and set about acquiring new customers for significantly less than this value.

Since its last raise on SyndicateRoom a little over 18 months ago, CN has grown direct-to-consumer revenue by more than 10 times. Capital raised in this latest round will be used to fuel further growth. The majority of funds raised would be spent on marketing, including scaling up of existing channels and the development of new digital channels. The company – which already boasts 50,000 users – hopes to increase resources of the new product development team and support senior hires.

The team

CN’s management team is led by Adam Cleevely who brings extensive experience in senior positions within small to medium companies. The team is expanding, with COO Danielle Miller and CTO Chris Godfrey having joined in January 2018. Both Danielle and Chris previously worked at Abcam, as Operations Director and Head of Software Development respectively. Completing the team is Chris Meaney, Head of Marketing, who has extensive experience in the space.

CEO Adam has extensive experience in small to medium companies. Following a stint as a Production Engineering Consultant with Newton Europe, he joined Abcam as a business analyst. He then ran Abcam’s Business Intelligence and Opportunities department and was responsible for large data analysis projects as well as project management. Adam then worked as Operations Director of Hubbub (an online food delivery business) for 18 months.

The lead investor

Lead investor Peter Keen is a Chartered Accountant with over 33 years’ experience managing and investing in technology businesses, primarily within the healthcare arena. In early 2016 he stepped down from his last full-time role as the founding Chief Executive of Cambridge Innovation Capital. Peter invested £50,000 into this round.

I knew Adam when he was at Abcam, and with Chairman Tim Dye having considerable experience in this market, this was a team I wanted to back. I made the right call as they have “delivered” in all its meanings, including building an incredibly competent and experienced team to manage growth.

Peter Keen

Lead investor

See current opportunities

Freedom One Life

EIS
Engineering & Manufacturing
Freedom One Life is developing a new generation of wheelchairs to empower those with physical disabilities to lead more independent, adventurous lives.

Active

Trading status

£40,288

Average investment

£282,016

Total raised

10to8

EIS
Software & Computer Services
All-in-one appointment scheduling software that’s already being used by over 2,000 companies in more than 30 countries and has facilitated over 1.6m appointments.

Active

Trading status

£23,478

Average investment

£586,942

Total raised

USIO

EIS
Environment & Renewables
A.I driven energy supply to UK households: for cheaper, greener, energy

Active

Trading status

£9,095

Average investment

£591,188

Total raised

The TenderSpace

EIS
Software & Computer Services
TenderSpace is a collaborative platform for the construction industry that brings together projects, people and products. The company raised capital on SyndicateRoom.

Active

Trading status

£21,000

Average investment

£482,996

Total raised

Cyance

EIS
Software & Computer Services
Cyance has created Nexus, a SaaS platform that monitors and stores signals across the web, ad networks and social media to build predictions from billions of behaviour signals.

Active

Trading status

£28,502

Average investment

£370,532

Total raised

Momentum Bioscience

EIS
Pharmaceuticals & Biotechnology
Momentum Bioscience overfunded on SyndicateRoom in November 2017. Read about the raise here.

Active

Trading status

£27,950

Average investment

£1,788,800

Total raised